Is Contineum Therapeutics, Inc. (CTNM) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.2% / 30% | 40.4% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 1.2% / 33% | 40.4% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 2.9% / 33% | 96.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 1.2% / 33% | 40.4% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 2.9% / 33% | 96.2% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -26.1% | |
| Return on Assets (ROA) | -17.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$55M |
| Free Cash Flow | -$56M |
| Total Debt | $8M |
| Debt-to-Equity | 3.2 |
| Current Ratio | 27.5 |
| Total Assets | $277M |
Price & Trading
| Last Close | $13.65 |
| 50-Day MA | $14.04 |
| 200-Day MA | $10.47 |
| Avg Volume | 272K |
|
52-Week Range
$3.35
| |
About Contineum Therapeutics, Inc. (CTNM)
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Contineum Therapeutics, Inc. (CTNM) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Contineum Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Contineum Therapeutics, Inc.'s debt ratio?
Contineum Therapeutics, Inc.'s debt ratio is 1.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.9%.
What are Contineum Therapeutics, Inc.'s key financial metrics?
Contineum Therapeutics, Inc. has a market capitalization of $498M. Return on equity stands at -26.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.